CRP and depressive symptom measurement: Most importantly, although anti-inflammatory interventions—for instance, infliximab—have shown promise in inflammatory subtypes of depression (e.g., patients with elevated CRP), prospective interventional trials targeting populations with depression–cancer comorbidity are conspicuously absent.